A patent review of RAF kinase inhibitors (2010–2018)

References

• Qin M, Zhai X, Xie H, et al. Design and synthesis of novel 2-(4-(2-(dimethylamino) ethyl)-4H-1, 2, 4-triazol-3-yl) pyridines as potential antitumor agents. Eur J Med Chem. 2014;81:47–58.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ye X, Tang N, et al. MOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer. Br J Pharmacol. 2014;10:171.
   Google Scholar
• Abdelazeem AH, El-Saadi MT, Said BG, et al. Novel diphenylthiazole derivatives with multi-target mechanism: synthesis, docking study, anticancer and anti-inflammatory activities. Bioorg Chem. 2017;75:127–138.
   PubMed Web of Science ®Google Scholar
• Rocca S, Carra G, Poggio P, et al. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as drug gable targets in atypical chronic myeloid leukemia. Mol Cancer. 2018;21:40.
   Google Scholar
• Karoulia Z, Gavathiotis E, Poulikakos PI, et al. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017;1(11):676–691.
   Google Scholar
• Luca DA, Maiello MR, D’Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl.2):17–27.
   Google Scholar
• Wagle N. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4:61–68.
   PubMed Web of Science ®Google Scholar
• Song C. Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discov. 2017;7:1248–1265.
   PubMed Web of Science ®Google Scholar
• Vandamme D, Herrero A, Al‑Mulla F, et al. Regulation of the MAPK pathway by RAF kinase inhibitory protein. Crit Rev Oncog. 2014;19:405‑15.
   PubMedGoogle Scholar
• Meng L, Huang Z. In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: a case study on the cancer MAPK signaling pathway. Comput Biol Chem. 2018;75:196–204.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–3290.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263–1284.
   PubMed Web of Science ®Google Scholar
• Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928–942.
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–3310.
   PubMed Web of Science ®Google Scholar
• Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16:281–298.
   PubMed Web of Science ®Google Scholar
• Shi H. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80–93.
   PubMed Web of Science ®Google Scholar
• Dang CV, Reddy EP, Shokat KM, et al. Drugging the “undruggable” cancer targets. Nat Rev Cancer. 2017;17(8):502–508.
   PubMed Web of Science ®Google Scholar
• Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63(15):4561–4567.
   PubMed Web of Science ®Google Scholar
• Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–867.
   PubMed Web of Science ®Google Scholar
• Frans NK, Klinte SM, Osterstr MA, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25(4):527–533.
   PubMed Web of Science ®Google Scholar
• Mikula M, Schreiber M, Husak Z, et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-RAF-1 gene. Embo J. 2001;20(8):1952–1962.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR. Mutations of the BRAF gene in human cancer. Nature. 2002;41:949–954.
   Google Scholar
• Boehringer II. B-RAF kinase inhibitors. US2013190286. 2013.
   Google Scholar
• Carter J, Tseng LH, Zheng G, et al. Non-p BRAF V600E mutations are common using a more sensitive and broad detection tool. Am J Clin Pathol. 2015;144:620–628.
   PubMed Web of Science ®Google Scholar
• Haydn JM. The MAPK pathway as an apoptosis enhancer in melanoma. Oncotarget. 2014;5:5040–5053.
   PubMedGoogle Scholar
• Lito P. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22:668–682.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387–390.
   PubMed Web of Science ®Google Scholar
• Shi H. Melanoma whole-exome sequencing identifies (V600E) BRAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
   PubMed Web of Science ®Google Scholar
• Waizenegger IC, Baum A, Steurer S, et al. A novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation. Mol Cancer Ther. 2016;15(3):354–365.
   PubMed Web of Science ®Google Scholar
• Sun QH, Zhu J. Identification and characterization of small-molecule inhibitors to selectively target the DFG-in over DFG-out conformation of the B-Raf kinase V600E mutant in colorectal cancer. Arch Pharm. 2016;349:808–815.
   PubMed Web of Science ®Google Scholar
• Desai J. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Target Oncol. 2015;10:179–188.
   PubMed Web of Science ®Google Scholar
• Wei H, Liu ZH, Liu B, et al. Promoter methylation and expression of Raf kinase inhibitory protein in esophageal squamous cell carcinoma. Oncol Lett. 2017;13:1866–1872.
   PubMed Web of Science ®Google Scholar
• Rahman R, Ung PM, Schlessinger A, et al. A web resource to investigate kinase conformations and inhibitor space. Nucleic Acids Res. 2019;47:361–366.
   Web of Science ®Google Scholar
• Rushworth LK, Hindley AD, O’Neill E, et al. Regulation and role of Raf-1/B-RAF heterodimerization. Mol Cell Biol. 2006;26:2262–2272.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacol Res. 2018;135:239–258.
   PubMed Web of Science ®Google Scholar
• Rukhlenko OS, Khorsand F, Krstic A, et al. Dissecting RAF inhibitor resistance by structure-based modeling reveals ways to overcome oncogenic RAS signaling. Cell Syst. 2018;7(2):161–179.
   PubMed Web of Science ®Google Scholar
• Asati V, Bharti SK, Mahapatra DK. Mutant B-Raf kinase inhibitors as anticancer agents. Anticancer Agents Med Chem. 2016;16:1558–1575.
   PubMed Web of Science ®Google Scholar
• Yen I, Shanahan F, Merchant M, et al. Pharmacological induction of RAS-GTP confers RAF inhibitor sensitivity in KRAS mutant tumors. Cancer Cell. 2018;34:611–625.
   PubMed Web of Science ®Google Scholar
• Karoulia Z, Wu Y, Ahmed TA, et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell. 2016;30:485–498.
   PubMed Web of Science ®Google Scholar
• Sanchez LB, Viros A, Girotti MR, et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014;7(318):30.
   Web of Science ®Google Scholar
• Hao H, Xiao D, Pan J, et al. Sentinel lymph node genes to predict prognosis in node- positive melanoma patients. Ann Surg Oncol. 2017;24(1):108.
   PubMed Web of Science ®Google Scholar
• Long GV. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014;5:5694.
   PubMed Web of Science ®Google Scholar
• Kemper K, Krijgsman O, Kong X, et al. BRAF(V600E) kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Cell Rep. 2016;16:263–277.
   PubMed Web of Science ®Google Scholar
• Marino KA, Sutto L, Gervasio FL. The effect of a widespread cancer-causing mutation on the inactive to active dynamics of the B-Raf kinase. J Am Chem Soc. 2015;137:5280–5283.
   PubMed Web of Science ®Google Scholar
• Wilson BJ, Schatton T, Zhan Q, et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 2011;71(15):5307.
   PubMed Web of Science ®Google Scholar
• Grasso M, Estrada MA, Ventocilla C, et al. Chemically linked vemurafenib inhibitors promote an inactive BRAFV600E conformation. ACS Chem Biol. 2016;11:2876–2888.
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80–93.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang K, Zhu X, et al. Encorafenib (LGX818), a potent braf inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016;370(2):332–344.
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103.
   PubMed Web of Science ®Google Scholar
• Wang XL, Kim J. Conformation-specific effects of RAF kinase inhibitors. Med Chem. 2012;55(17):7332–7341.
   Web of Science ®Google Scholar
• Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227–235.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–4038.
   PubMed Web of Science ®Google Scholar
• Tang Z, Yuan X, Du R, et al. BGB-283, a novel RAF kinase and EGFR inhibitor, displays potent antitumor activity in BRAF-mutated colorectal cancers. Mol Cancer Ther. 2015;14(10):2187–2197.
   PubMed Web of Science ®Google Scholar
• Sclafani F, Gullo G, Sheahan K, et al. B-Raf mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol. 2013;87:55–68.
   PubMed Web of Science ®Google Scholar
• Barras D. BRAF mutation in colorectal cancer: an update. Biomarkers Cancer. 2015;7(Suppl. 1):9–12.
   PubMedGoogle Scholar
• Rosenbaum E, Hosler G, Zahurak M, et al. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol. 2004;18(7):898–902．.
   Web of Science ®Google Scholar
• Fiskus W, Mitsiades N. B-Raf inhibition in the clinic: present and future. Annu Rev Med. 2016;67:29–43.
   PubMed Web of Science ®Google Scholar
• Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;14:209–221.
   Google Scholar
• Pulici M, Traquandi G, Marchionni C, et al. Optimization of diarylthiazole B-Raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated HERG inhibition, and low paradoxical effect. Chem Med Chem. 2015;10(2):276–295.
   Google Scholar
• Lamian K, Keller JM, Mizokami A, et al. Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types. Crit Rev Oncog. 2014;19:455–468.
   PubMedGoogle Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
   PubMed Web of Science ®Google Scholar
• Guo W, Dong Z, Lin X, et al. Decreased expression and aberrant methylation of Raf kinase inhibitory protein gene in esophageal squamous cell carcinoma. Cancer Invest. 2012;30:703–711.
   PubMed Web of Science ®Google Scholar
• Nieto P, Ambrogio C, Esteban-Burgos L, et al. Braf kinase-inactive mutant induces lung adenocarcinoma. Nature. 2017;548(7666):239–243.
   PubMed Web of Science ®Google Scholar
• Okimoto RA, Lin L, Olivas V, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci. 2016;113(47):13456–13461.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26–48.
   PubMed Web of Science ®Google Scholar
• Shaw AS, Kornev AP, Hu J, et al. Kinases and pseudo kinases: lessons from RAF. Mol Cell Biol. 2014;34:1538–1546.
   PubMed Web of Science ®Google Scholar
• Holderfield M, Deuker MM, McCormick F, et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455–467.
   PubMed Web of Science ®Google Scholar
• Hatzl S, Geiger O, Kuepper MK, et al. Increased expression of miR-23a mediates a loss of expression in the RAF kinase inhibitor protein RKIP. Cancer Res. 2016;76:3644–3654.
   PubMed Web of Science ®Google Scholar
• Huang TG, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. Hematol Oncol. 2013;6:30.
   Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–1876.
   PubMed Web of Science ®Google Scholar
• Davis JE, Anderson JE, Kim KB. Dabrafenib therapy for advanced melanoma. Ann Pharmacother. 2014;48(4):519–529.
   PubMed Web of Science ®Google Scholar
• Lidsky M, Antoun G, Speicher P, et al. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. J Biol Chem. 2014;289(40):27714–27726.
   PubMed Web of Science ®Google Scholar
• Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873–886.
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639.
   PubMed Web of Science ®Google Scholar
• Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909–920.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Festino L, et al. MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol. 2017;18:745–754.
   PubMed Web of Science ®Google Scholar
• Thompson SK, Smith RA, Reddy S, et al. Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. WO2014169167 A1. 2014.
   Google Scholar
• Abdul RN, Danielle MF, Carolyn MZ, et al. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEKinhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunol Ther Cancer. 2019;7:4.
   PubMed Web of Science ®Google Scholar
• Baselga J. Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder. WO2014089570 A1. 2014.
   Google Scholar
• Stadtmueller H. New azyindolylphenyl sulfonamides as serine/threonine kinase inhibitors. WO2012/104388 A1. 2012.
   Google Scholar
• Stadtmueller H. [AT] azindolylphenyl sulfonamides as serine/threonine kinase inhibitors. US2013029993 A1. 2013.
   Google Scholar
• Ibrahim PN, Zhang C, Spevak W, et al. PLX-8394 or PLX-7904 for use in the treatment of BRAF-V600-related diseases. WO2016191296. 2016.
   Google Scholar
• Stadtmueller H. immunoresponsive methods of treating tumors. US20180318273 A1. 2018.
   Google Scholar
• Springer CJ, Marais R, Girotti R, et al. 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[3-oxo-4H-pyrido[2,3-B] pyrazine-8-yl] oxy] phenyl] urea derivatives as RAF inhibitors for the treatment of cancer. WO 2015075483 A1. 2015.
   Google Scholar
• Wong H, Belvin M, Herter S, et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009;329(1):360–367.
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009 Apr 1;69(7):3042–3051.
   PubMed Web of Science ®Google Scholar
• Sung PH, Soon KA. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF V600E mutant cancer. Life Sci. 2017;183:37–44.
   PubMed Web of Science ®Google Scholar
• Novartis A. Biaryl amide compounds as kinase inhibitors. WO2014151616 A1. 2014.
   Google Scholar
• Eli LC. 2-Amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as RAF kinase inhibitors. WO2013134243. 2013.
   Google Scholar
• Eli LC. Raf inhibitor compounds. US2015105367. 2015.
   Google Scholar
• Cho KJ, Kasal RS, Park JH, et al. Raf inhibitors target RAS spatiotemporal dynamics. Curr Biol. 2012;22(11):945–955.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Gordon MS. Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014;33:1–8.
   Google Scholar
• Ishii N, Harada N, Joseph EW, et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 2013;73(13):4050–4060.
   PubMed Web of Science ®Google Scholar
• Murakata M, Ikeda T, Ichige T. Method for producing coumarin derivative. EP2754654 A1. 2014.
   Google Scholar
• Nomura D, Roberts L, Ward C. Compositions for treating breast cancer. WO2018148598 A1. 2018.
   Google Scholar
• Miller CR. FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/RAF inhibitor, RO5126766 (CH5126766), in preclinical xenograft models. Gynecol Oncol. 2014;133(1):128–137.
   PubMed Web of Science ®Google Scholar
• Hoos A. Combinations of an anti-pd-l1 antibody and a MEK inhibitor and/ora BRAF inhibitor. WO2014195852. 2014.
   Google Scholar
• Honda K, Yamamoto N. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual RAF/MEK inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015;72(3):577–584.
   Web of Science ®Google Scholar
• Ambit BC. Raf kinase modulator compounds and methods of use thereof. US2017298029. 2017.
   Google Scholar
• Bae IH, Ahn YG, GwangMo N, et al. Antitumor activity of the selective RAF inhibitor HM95573 in melanoma. Cancer Res. 2015;75(15 Suppl):2606.
   Google Scholar
• Lee YM, Bae I, Mo NG, et al. Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies. Cancer Res. 2015;75(15Suppl.):2607.
   PubMedGoogle Scholar
• Yuan X, Tang Z, Du R, et al. BGB-283 effectively enhances MEK inhibitor induced tumor suppression in RAS mutant cancers. Cancer Res. 2015;75(15 Suppl):669.
   Google Scholar
• Zhou CY, Wang SH, Zhang GL. Fused tricyclic compounds as RAF kinase inhibitors. WO 2013097224 A1. 2013.
   Google Scholar
• Zhou CY, Wang SH, Zhang GL. Fused tricyclic compounds as RAF kinase inhibitors. US2015045355 A1. 2015.
   Google Scholar
• Zhou CY, Wang SH, Zhang GL. Condensed tricyclic compounds as RAF kinase inhibitors. CN105348299 A. 2016.
   Google Scholar
• Hoos A. Combinations of an anti-pd-l1 antibody and a MEK inhibitor and/or a BRAF inhibitor. WO2014195852. 2014.
   Google Scholar
• Peng SB, Henry JR, Kaufman MD, et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell. 2015;28(3):384–398.
   PubMed Web of Science ®Google Scholar
• Henry JR, Kaufman MD, Peng SB, et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino) pyrido [2,3-d] pyrimidin-6-yl) phenyl) urea (LY3009120) as a Pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. J Med Chem. 2015;58(10):4165–4179.
   PubMed Web of Science ®Google Scholar
• Allgeier MC, Flynn DL, Kaufman MD, et al. 2-Amino, 6-phenyl substituted pyrido[2,3-d], pyrimidine derivatives useful as RAF kinase inhibitors. WO2013134243 A1. 2013.
   Google Scholar
• Garraway L, Emery C, Wagle N. MEK1 mutation conferring resistance to RAF and MEK inhibitors. US2013143911 A1. 2013.
   Google Scholar
• Russu WA, Shallal HM. Piperazinylpyrimidine analogues as protein kinase inhibitors. US2012053183 A1. 2012.
   Google Scholar
• Sim TB, Ham YJ, Yoo KH, et al. Novel 1,6-disubstituted indole compounds as protein kinase inhibitors. WO2011052923 A2. 2011.
   Google Scholar
• Emery C, Antony R. Garraway L.C-RAF mutants that confer resistance to RAF inhibitors. US2015133478 A1. 2015.
   Google Scholar
• Mordant P. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010;9(2):358–368.
   PubMed Web of Science ®Google Scholar
• Zitzmann K. The novel RAF inhibitor RAF265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocri Related Cancer. 2011;18(2):277–285.
   PubMed Web of Science ®Google Scholar
• Ibrahim PN, Visor GC. Solid forms of a compound for modulating kinases. US2016340357 A1. 2016.
   Google Scholar
• Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526(7574):583–586.
   PubMed Web of Science ®Google Scholar
• Ibrahim PN, Zhang C, Spevak W, et al. Kinase modulation, and indications therefor. US2016339025 A1. 2016.
   Google Scholar
• Merat P. Agents enhancing hur/elav protein levels for use in the treatment of BRAF-mutated cancers. EP3375455 A1. 2018.
   Google Scholar
• Bierlmaier SL, Haltiwanger PC, Jacobs M. Solid state forms of a quinazoline derivative and its use as a BRAF inhibitors. WO2014164648 A2. 2014.
   Google Scholar
• Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526:583–586.
   PubMed Web of Science ®Google Scholar
• Kim DH, Siim T. Novel small molecule RAF kinase inhibitors for targeted cancer therapeutics. Arch Pharmacal Res. 2012;35(4):605–615.
   PubMed Web of Science ®Google Scholar
• James J, Ruggeri B, Armstrong RC, et al. CEP-32496: a novel orally active BRAFV600E inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther. 2012;11(4):930–941.
   PubMed Web of Science ®Google Scholar
• Rowbottom MW, Faraoni R, Chao Q, et al. Identification of 1-(3-(6, 7-dimethoxyquinazo-lin-4-yloxy) phenyl)-3-(5-(1, 1, 1-trifluoro-2- methylpropan-2-yl) isoxazol-3-yl) urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J Med Chem. 2012;55(3):1082–1105.
   PubMed Web of Science ®Google Scholar
• Tambe M, Karjalainen E, Vaha-Koskela M, et al. Paradox-Breaker Pan-RAF inhibitors induce an AML-specific cytotoxic response and synergize with venetoclax to display superior antileukemic activity. Blood. 2018;132:2210.
   Web of Science ®Google Scholar
• Stuart DD, Li N, Poon DJ, et al. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor. Cancer Res. 2012;72(8 Suppl):3790.
   Google Scholar
• Dummer R, Robert C, Nyakas M, et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with B-RAFV600 mutant advanced or metastatic melanoma. J Clin Oncol. 2013;31(Suppl):9028.
   Google Scholar
• Duncan JS, Whittle MC, Nakamura K, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149:307–321.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Hulme C, Hurley LH, et al. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec (R), Nexavar (R), and BIRB-796. Bioorg Med Chem. 2010;18(15):5738–5748.
   PubMed Web of Science ®Google Scholar
• Basile KJ. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014 May;27(3):479–484.
   PubMed Web of Science ®Google Scholar
• Okimoto RA. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016;22(47):13456–13461.
   Google Scholar
• James J. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther. 2012;11(4):930–941.
   PubMed Web of Science ®Google Scholar
• Ishii N. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 2013;73(13):4050–4060.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Takeda P. Administration of a RAF inhibitor and a MEK inhibitor in the treatment of melanoma. US2015126533. 2015.
   Google Scholar
• Kim JS, Choi GH, Jung Y, et al. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. J Cancer ResClin Oncol. 2018;144:1487–1501.
   PubMed Web of Science ®Google Scholar